In only a few months, Genzeva's new breakthrough advanced genomics process integrating RYLTI's innovative RKE (RYAILITI Knowledge Engineering) AI Platform and digital twin ecosystem has again illustrated major potential for accelerating discovery in genomic research.

在短短的几个月里，Genzeva的新突破性先进基因组学过程整合了RYLTI的创新RKE（RYAILITI知识工程）AI平台和数字双胞胎生态系统，再次显示了加速基因组研究发现的主要潜力。

ROCKVILLE, Md., Nov. 15, 2023 /PRNewswire/ -- Findings from a second joint study by Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, and tech innovator RYLTI again illustrate the potential of their breakthrough process to accelerate discovery in genomic research..

ROCKVILLE，Md.，2023年11月15日/PRNewswire/-由Genzeva进行的第二项联合研究的结果，Genzeva是一家领先的分子遗传实验室，为临床诊断和研究进行全基因组和临床外显子组测序，技术创新者RYLTI再次说明他们的突破过程有可能加速基因组研究中的发现。。

It has been only a few months since the Genzeva/RYLTI partnership's first study yielded success identifying a biomarker for the diagnosis of a multifactorial disorder, and a possible hotspot, by applying innovative new methodology including the use of RYLTI's RKE (RYAILITI Knowledge Engineering) AI Platform and biomimetic digital twin ecosystem..

自Genzeva/RYLTI合作伙伴关系的第一项研究成功确定诊断多因素疾病的生物标志物和可能的热点以来，仅仅几个月，通过应用创新的新方法，包括使用RYLTI的RKE（RYAILITI知识工程）AI平台和仿生数字双胞胎生态系统。。

The new study investigated a different multifactorial disorder. Again, led by geneticist Dr. William G. Kearns, Co-founder, Chief Executive Officer and Chief Scientific Officer of Genzeva, a patent-pending process was utilized which employed whole genome or clinical exome sequencing, phenotype-driven variant analysis and ranking, and the RKE Platform.

这项新研究调查了另一种多因素疾病。再次，由Genzeva的遗传学家William G.Kearns博士，联合创始人，首席执行官和首席科学官领导，利用了一个专利申请过程，该过程采用了全基因组或临床外显子组测序，表型驱动的变异分析和排名，以及RKE平台。

RYLTI's methodology incorporates human intelligence without bias into the analytical workflow and leverages complex data from diverse sources in a way that RYLTI believes many traditional AI and Machine Learning technologies are not engineered to recognize..

RYLTI的方法将人类智能无偏见地纳入分析工作流程，并利用来自不同来源的复杂数据，RYLTI认为许多传统的人工智能和机器学习技术并未被设计为识别。。

The analysis identified DNA variants in six genes classified as variants of unknown clinical significance (VUS), which were not present in controls. This discovery shows that the molecular actions of these six VUSs are closely associated with the pathophysiology of the multifactorial disease under investigation, and could be reclassified as pathogenic.

该分析确定了六个基因中的DNA变异体，这些变异体被归类为临床意义未知（VUS）变异体，而这些变异体在对照中不存在。这一发现表明，这六个VUS的分子作用与所研究的多因素疾病的病理生理密切相关，可以重新分类为致病性。

.

.

'Our second study once again illustrates that this novel process and pioneering technology for genomic analyses can uncover hidden 'dark data' with insights that may never have been achievable before. We feel this exciting new application may have far-reaching potential to expand the scope of discovery in research, perform virtual clinical trials, and aid in the rapid identification of new therapies for the effective treatment of disease,' said Kearns..

“我们的第二项研究再次表明，这一新颖的过程和基因组分析的开创性技术可以揭示隐藏的“暗数据”，其见解可能是以前无法实现的。Kearns说，我们认为这个令人兴奋的新应用可能具有深远的潜力，可以扩大研究发现范围，进行虚拟临床试验，并有助于快速确定有效治疗疾病的新疗法。。

'Having another genomic research breakthrough with our partner Genzeva only a few months since our initial success together is very exciting. RYLTI 'dark data' discoveries are being made in other sectors as well, and the use of our game-changing technology has proven to have broad applications,' said Peter Fiorillo, President and CEO of RYLTI..

“与我们的合作伙伴Genzeva进行另一项基因组研究突破仅仅几个月，因为我们最初的成功在一起是非常令人兴奋的。RYLTI的总裁兼首席执行官Peter Fiorillo说，RYLTI的“黑暗数据”发现也正在其他领域进行，我们改变游戏规则的技术的使用已被证明具有广泛的应用。。

RYLTI has engaged US Capital Global Partners LLC as RYLTI's financial advisor.

RYLTI已聘请美国资本全球合作伙伴有限责任公司作为RYLTI的财务顾问。

About GENZEVA

关于GENZEVA

GENZEVA is a leading molecular diagnostic laboratory utilizing advanced genetic sequencing methods, bioinformatics platforms, and patent-pending technology solutions. It provides services to healthcare research organizations worldwide, clinicians, and referring laboratories.

GENZEVA是利用先进的基因测序方法，生物信息学平台和正在申请专利的技术解决方案的领先分子诊断实验室。它为全球医疗保健研究机构，临床医生和转诊实验室提供服务。

About RYLTI

关于RYLTI

RYLTI is a provider of advanced analytics solutions featuring multi-dimensional modeling, small wide data, knowledge graphing, and biomimetic computing methods. It delivers solutions to customers in multiple industries via its patent-pending RKE (RYAILITI Knowledge Engineering) AI Platform.

RYLTI是一家先进的分析解决方案提供商，具有多维建模，小数据，知识绘图和仿生计算方法。它通过其正在申请专利的RKE（RYAILITI知识工程）AI平台为多个行业的客户提供解决方案。

For more information, visit genzeva.com and ryailiti.com.

欲了解更多信息，请访问genzeva.com和ryailiti.com。

Dr. Kearns will attend the American Molecular Pathology 2023 annual meeting from November 15–18, 2023.

Kearns博士将于2023年11月15日至18日参加美国分子病理学2023年会。

Genzeva Contact:Dr. William G. Kearns [email protected]

Genzeva联系人：Dr。William G.Kearns[电子邮件保护]

RYLTI / RYAILITI Contact:Peter Fiorillo [email protected]

RYLTI/RYAILITI联系人：Peter Fiorillo[电子邮件保护]

SOURCE RYLTI

源RYLTI